期刊
JOURNAL OF SURGICAL ONCOLOGY
卷 119, 期 2, 页码 222-231出版社
WILEY
DOI: 10.1002/jso.25298
关键词
adjuvant therapy; melanoma
资金
- GSK
- Celldex
- Merck
- Theraclion
- 3M
- BMS
- Dynavax
- Genetech
- Incyte
- Immunocore
- Reata
There has been a rapid increase in adjuvant therapies approved for treatment following surgical resection of stages III/IV melanoma. We review current indications for adjuvant therapy, which currently includes a heterogenous group of stages III and IV patients with melanoma. We describe several pivotal clinical trials of systemic immune therapies, targeted immune therapies, and adjuvant vaccine strategies. Finally, we discuss the evidence for selecting the most appropriate treatment regimen(s) for the individual patient.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据